Riliprubart (SAR 445088) is an anti-C1s humanized IgG4 monoclonal antibody that inhibits activated C1s in the proximal portion of the classical complement system. Riliprubart selectively inhibits activated C1s and prevents the enzymatic action of C1 on its substrates C4 and C2, thus inhibiting the formation of the classical pathway C3 convertase, C4b2a. Riliprubart can be used to study complement-mediated diseases such as systemic lupus erythematosus. Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003)[1].
Molecular Weight:
(145.52 kDa)
Purity:
99.90
CAS Number:
[2756228-76-7]
Target:
Complement System
Application Notes:
MCE Product type: Inhibitory Antibodies
* VAT and and shipping costs not included. Errors and price changes excepted
